Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 4Terminated 3

Sponsor Class

OTHER 33NIH 7INDUSTRY 4NETWORK 2OTHER_GOV 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Melanoma 2Recurrence 1Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 393Docetaxel 385Cisplatin 358pembrolizumab 341Bevacizumab 334Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 212Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147atezolizumab 145Ipilimumab 145Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 117Bortezomib 117Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Introns × Clear all
NCT03066947 2021-01-29

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

BriaCell Therapeutics Corporation

Phase 1/2 Completed
24 enrolled 12 charts
Breast

Breast Neoplasms

NCT00749684 2015-10-19

Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)

Merck Sharp & Dohme LLC

Completed
138 enrolled 6 charts
Dermatologic

Melanoma

NCT00723710 2015-08-26

Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)

Merck Sharp & Dohme LLC

Completed
299 enrolled 5 charts
Dermatologic

Melanoma

NCT00329368 2012-03-09

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Endocyte

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡